Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.

Nature medicine - 1 Dec 2015

Wen Qiang Jeremy, Yang Qiong, Goldenson Benjamin, Malinge Sébastien, Lasho Terra, Schneider Rebekka K, Breyfogle Lawrence J, Schultz Rachael, Gilles Laure, Koppikar Priya, Abdel-Wahab Omar, Pardanani Animesh, Stein Brady, Gurbuxani Sandeep, Mullally Ann, Levine Ross L, Tefferi Ayalew, Crispino John D

Abstract excerpt

Primary myelofibrosis (PMF) is characterized by bone marrow fibrosis, myeloproliferation, extramedullary hematopoiesis, splenomegaly and leukemic progression. Moreover, the bone marrow and spleens of individuals with PMF contain large numbers of atypical megakaryocytes that are postulated to contribute to fibrosis through the release of cytokines, including transforming growth factor (TGF)-β. Although the Janus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Aurora Kinase A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azepines

Share to Cost of Illness

Share to Megakaryocytes

Share to Nitriles

Share to Primary Myelofibrosis

Share to Receptors, Thrombopoietin

Source

Open in PubMed Open full text

Identifiers

PMID: 26569382
DOI: 10.1038/nm.3995
PMCID: PMC4674320

Genes

AURKA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.PMID 26569382Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

The Role of Megakaryocytes in Myelofibrosis.Semantic proximity Read ↗

'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.Semantic proximity Read ↗

Novel therapies for myelofibrosis.Semantic proximity Read ↗

JAK2V617F mutant megakaryocytes contribute to hematopoietic aging in a murine model of myeloproliferative neoplasmSemantic proximity Read ↗

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.Semantic proximity Read ↗

Janus activated kinase inhibition in myelofibrosis.Semantic proximity Read ↗

Targeting hedgehog signaling in myelofibrosis and other hematologic malignanciesSemantic proximity Read ↗

Inhibition of RhoA-mediated secretory autophagy in megakaryocytes mitigates myelofibrosis in miceSemantic proximity Read ↗

Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis.Semantic proximity Read ↗

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.Semantic proximity Read ↗

Aberrant splicing of CHEK1 is a driver of megakaryocytic dysplasia in U2AF1S34F mutant myelodysplastic neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.